{"id":1441,"date":"2022-11-15T11:20:27","date_gmt":"2022-11-15T17:20:27","guid":{"rendered":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/?p=1441"},"modified":"2022-12-13T11:21:34","modified_gmt":"2022-12-13T17:21:34","slug":"pfizer-nabs-rsv-therapeutic-biotech-reviral-in-quick-525m-bolt-on","status":"publish","type":"post","link":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/2022\/11\/15\/pfizer-nabs-rsv-therapeutic-biotech-reviral-in-quick-525m-bolt-on\/","title":{"rendered":"Pfizer nabs RSV therapeutic biotech ReViral in quick $525M bolt-on"},"content":{"rendered":"<div class=\"panel body-content\"><div class=\"panel__container\">\n<p>(<a href=\"https:\/\/www.fiercebiotech.com\/biotech\/pfizer-nabs-rsv-therapeutic-biotech-reviral-quick-525m-bolt\">Fierce Biotech<\/a>) Pfizer has had\u00a0<a href=\"https:\/\/www.fiercebiotech.com\/biotech\/pfizer-prepares-leave-gsk-dust-maternal-rsv-vax-granted-fda-breakthrough-tag\">plenty of success<\/a>\u00a0in respiratory syncytial virus (RSV) lately, with multiple FDA designations and clinical advancements for its vaccine candidate. But that\u2019s not enough for the pharma giant. Today, the New York-based behemoth is acquiring ReViral and its collection of therapeutics for the pesky respiratory virus for $525 million.<\/p>\n<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>(Fierce Biotech) Pfizer has had\u00a0plenty of success\u00a0in respiratory syncytial virus (RSV) lately, with multiple FDA designations and clinical advancements for its vaccine candidate. But that\u2019s not enough for the pharma giant. Today, the New York-based behemoth is acquiring ReViral and its collection of therapeutics for the pesky respiratory virus for $525 million.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[47],"tags":[],"class_list":["post-1441","post","type-post","status-publish","format-standard","hentry","category-rsv-therapies"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/1441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/comments?post=1441"}],"version-history":[{"count":1,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/1441\/revisions"}],"predecessor-version":[{"id":1442,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/1441\/revisions\/1442"}],"wp:attachment":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/media?parent=1441"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/categories?post=1441"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/tags?post=1441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}